This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Sandbox 20001
From Proteopedia
(Difference between revisions)
| Line 16: | Line 16: | ||
== Recent published papers == | == Recent published papers == | ||
| - | * A study by Zhou and colleagues on the structural basis for the recognition of the SARS-CoV-2 | + | * A study by Zhou and colleagues on the structural basis for the recognition of the SARS-CoV-2 (COVID-19) by full-length human ACE2 gives insights to the molecular basis for coronavirus recognition and infection<ref>PMID:32132184</ref>. |
* A recent study by Gautret ''et al''. (2020) showed, despite its small sample size (20 patients treated), that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.<ref>Gautret, ''et al.'' "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial: Intl J Antimcrob Agents" (in press) 2020 [http://dx.doi.org/10.1016/j.ijantimicag.2020.105949]</ref> | * A recent study by Gautret ''et al''. (2020) showed, despite its small sample size (20 patients treated), that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.<ref>Gautret, ''et al.'' "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial: Intl J Antimcrob Agents" (in press) 2020 [http://dx.doi.org/10.1016/j.ijantimicag.2020.105949]</ref> | ||
* Scientists are endeavoring to find antivirals specific to the virus. Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of COVID-19 in China; the summary of some promising results are summarized.<ref>PMID:32147628</ref> | * Scientists are endeavoring to find antivirals specific to the virus. Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of COVID-19 in China; the summary of some promising results are summarized.<ref>PMID:32147628</ref> | ||
| - | |||
Revision as of 11:13, 21 March 2020
Coronavirus Disease 2019 (COVID-19)
| |||||||||||
References
- ↑ Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 4. pii: science.abb2762. doi: 10.1126/science.abb2762. PMID:32132184 doi:http://dx.doi.org/10.1126/science.abb2762
- ↑ Gautret, et al. "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial: Intl J Antimcrob Agents" (in press) 2020 [1]
- ↑ Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60. doi: 10.5582/ddt.2020.01012. PMID:32147628 doi:http://dx.doi.org/10.5582/ddt.2020.01012
